About this event
Advances in Precision Oncology for Blood Cancers
Tuesdays the 6th, 13th and 20th June at 3pm BST/ 4pm CET/ 10am EST
There is a clinical need to improve our ability to diagnose and treat blood cancers with highly effective treatments. In this webinar series, we will highlight the trends that are paving the way for precision oncology in blood cancers with examples within specific disease areas. We will also showcase opportunities for the future, and how this will improve overall patient benefit. This webinar series will include a comprehensive review of blood cancers and the implementation of therapy and testing in the UK and abroad.
By joining you will:
**Please note that by registering for the first webinar in the series you will automatically gain access to all subsequent webinars. **
Webinar 1: Precision Medicine in Acute Myeloid Leukaemia
Tuesday 6th June at 3pm BST/ 4pm CET/ 10am EST
Acute myeloid leukaemia (AML) is the predominant form of acute leukaemia among adults. It is characterised by rapid progression and necessitates prompt intervention. The webinar assesses the current state of precision medicine and immunotherapy in AML, emphasising avenues for enhancing diagnostic and treatment approaches. Moreover, it will highlight the advantages that patients can presently derive from these advancements as well as their potential future benefits.
Talk Title: New insights in NPM1-mutated AML
Brunangelo Falini, Head of the Institute of Hematology and Bone Marrow Transplantation, University and Hospital of Perugia
Talk Title: Selective Homing of CAR-CIK Cells to The Bone Marrow Niche Enhances Control of The Acute Myeloid Leukemia Burden
Andrea Biondi, Professor, University of Milano-Bicocca
Webinar 2: Precision Medicine in Chronic Myeloid Leukaemia
Tuesday 13th June at 3pm BST/ 4pm CET/ 10am EST
Chronic myeloid leukaemia (CML) is a blood cancer characterised by a gradual growth rate that spans several years. When detected at an early stage the prognosis for a 5-year survival is generally favourable, and precision medicine presents novel possibilities for prolonging this life expectancy. This webinar will cover the advances in precision medicine for CML as well as their implementation in the clinic.
Talk title: Trends and Opportunities in the Treatment of CML
Gillian Horne, Clinical Senior Research Fellow, Paul O'Gorman Leukaemia Research Centre, University of Glasgow
Talk title: Clinical Diagnostic Testing in CML: Current Methods of Diagnosis and Management
Robert Dunn, Head of Cytogenetics, King's College Hospital Nhs Foundation Trust
Talk title: Updates on the Management of Chronic Myeloid Leukaemia
Fadi G. Haddad, Assistant Professor, The University of Texas MD Anderson Cancer Center
Webinar 3: Precision Medicine in Myeloproliferative Neoplasms
Tuesday 20th June at 3pm BST/ 4pm CET/ 10am EST
Myeloproliferative neoplasms (MPNs) encompass a collection of uncommon blood disorders. While officially categorised as blood cancers by the World Health Organization (WHO), individuals with MPNs frequently experience a relatively good state of well-being, and the prognosis may differ based on the rate of disease advancement. This webinar will explore the precision medicine and immunotherapy strategies available for addressing MPNs.
Talk Title: Momelotinib: The Case for a 4th JAK Inhibitor
Aaron T. Gerds, MD, Associate Professor of Medicine, Hematology & Medical Oncology, Deputy Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute
Talk Title: Tumor Antigen-Specific T-Cell Immunity in The Context Of Myeloproliferative Neoplasms
Cansu Cimen Bozkus, Assistant Professor, Icahn School of Medicine at Mount Sinai
This webinar series is kindly sponsored by QIAGEN
Hosted by
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events and webinars. We also produce reports and operate a content-rich website.